Equities

Agile Therapeutics Inc

AGRX:PKC

Agile Therapeutics Inc

Actions
  • Price (USD)0.3777
  • Today's Change-0.022 / -5.47%
  • Shares traded20.37k
  • 1 Year change-91.39%
  • Beta1.2284
Data delayed at least 15 minutes, as of May 17 2024 20:41 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.

  • Revenue in USD (TTM)21.50m
  • Net income in USD-7.79m
  • Incorporated1997
  • Employees19.00
  • Location
    Agile Therapeutics Inc500 College Road East, Suite 310PRINCETON 08540-6635United StatesUSA
  • Phone+1 (609) 683-1880
  • Fax+1 (302) 736-9883
  • Websitehttps://www.agiletherapeutics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Aoxing Pharmaceutical Company Inc30.11m-1.46m2.46m339.00--0.0287--0.0816-0.0192-0.01920.39510.25070.4962.322.56---2.41-14.54-7.06-35.4576.1968.51-4.85-37.690.73680.33870.6052--26.8837.20-62.49---38.80--
SYBLEU Inc11.70k-307.88k2.46m--------210.27-0.0293-0.02930.0011-0.03670.0641-------168.63-----------2,631.45-----8.484.96--0.00--26.51------
InMed Pharmaceuticals Inc5.63m-6.08m2.46m13.00--0.1685--0.4381-1.23-1.230.92841.750.40062.7129.77---43.26-88.10-50.03-104.1939.20---108.01-1,066.115.80--0.00--279.60--57.27--29.56--
Applied DNA Sciences Inc5.52m-12.50m2.47m53.00------0.4479-17.13-17.137.67-0.05580.389310.384.64104,110.80-87.15-88.57-111.09-121.9133.9844.35-223.89-113.261.54-------26.4327.92-18.73--33.80--
Gamida Cell Ltd1.78m-63.00m2.53m145.00------1.42-0.6582-0.65820.0162-0.02040.0157----12,303.45-55.51-56.15-71.23-67.6218.50---3,531.17-18,390.582.09--1.04------20.63---8.05--
Qrons Inc0.00-789.36k2.53m2.00---------0.0581-0.05810.00-0.1090.00----0.00-45,235.53-1,513.45---------------5.76---------7.61------
Aridis Pharmaceuticals Inc22.36m-1.14m2.56m37.00------0.1144-0.1845-0.18450.7074-0.26482.40--58.45604,297.30-12.24-120.16---678.29-----5.11-1,559.63--------101.3729.1634.43---34.84--
CNS Pharmaceuticals Inc0.00-17.46m2.57m3.00---------3.58-3.580.00-0.41530.00----0.00-384.86-132.47---185.75---------------------23.42------
Lucy Scientific Discovery Inc16.73k-9.76m2.58m----31.74--154.01-6.34-7.210.01030.0460.0037--0.7276---215.45------49.97---58,360.55-----5.100.4615-------53.49------
DSwiss Inc1.47m-49.54k2.59m11.00--45.84157.511.76-0.0002-0.00020.00710.00033.92154.8254.81133,643.60-13.22-8.69-50.26-45.4724.4425.55-3.37-2.471.05-15.740.3961---20.5046.20-688.36---66.17--
Agile Therapeutics Inc21.50m-7.79m2.59m19.00------0.1205-3.65-3.656.98-1.511.632.905.421,131,316.00-59.25-94.24---142.6259.73---36.26-513.500.3843------80.02--43.08------
Navidea Biopharmaceuticals Inc610.00-8.81m2.60m11.00------4,265.89-0.2086-0.05470.00001-0.03270.00010.15290.006655.45-143.97-169.68---753.52-8,103.2891.34-1,411,062.00-1,938.530.5066-------87.65-48.49-46.75--63.23--
Windtree Therapeutics Inc0.00-20.29m2.66m15.00--7.94-----8.21-8.210.000.56550.00----0.00-57.68-44.51-63.50-48.38-------94,533.34----0.8179------48.25------
AgriFORCE Growing Systems Ltd16.28k-11.73m2.69m7.00--0.0705--165.21-14.14-14.140.0141.470.0008--0.4082,325.71-59.84-78.95-84.37-109.8616.58---72,071.25-243,182.500.6922-1.390.3253------8.85--48.61--
60 Degrees Pharmaceuticals Inc253.57k-3.99m2.73m3.00------10.77-0.6657-0.66570.04560.83820.05590.96381.8384,523.34-84.00-------87.15---1,504.04--2.39-1.890.0321---50.40--35.51------
Data as of May 17 2024. Currency figures normalised to Agile Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
BBVA Asset Management SA SGIICas of 31 Dec 202349.000.00%
BG Fund Management Luxembourg SAas of 31 Dec 202343.000.00%
FSC Securities Corp.as of 30 Sep 20234.000.00%
Tower Research Capital LLCas of 31 Mar 20240.000.00%
Group One Trading LPas of 31 Mar 20240.000.00%
UBS Securities LLCas of 31 Mar 20240.000.00%
Citadel Securities LLCas of 31 Mar 20240.000.00%
RBC Dominion Securities, Inc.as of 31 Mar 20240.000.00%
Advisory Services Network LLCas of 31 Mar 20240.000.00%
CWM LLCas of 31 Mar 20240.000.00%
More ▼
Data from 30 Sep 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.